No Data
No Data
Fanpep - In the second quarter, the company is conducting preclinical trials with the goal of starting clinical trials for FPP004X in Japan in the first quarter of 2025.
On the 8th, Fanpep <4881> announced its consolidated results for the second quarter of the fiscal year ending December 2024 (January-June 24). Revenue was 0 billion yen (compared to 0 billion yen for the same period last year), operating loss was 0.395 billion yen (compared to a loss of 0.622 billion yen for the same period last year), ordinary loss was 0.382 billion yen (compared to a loss of 0.589 billion yen for the same period last year), and the interim net loss attributable to parent company shareholders was 0.379 billion yen (compared to a loss of 0.585 billion yen for the same period last year) for the antibody-induced peptide project, the antibody-induced peptide "FPP003" (
Stable, significant rise in US stocks may improve investor sentiment.
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a strong performance. In yesterday's US stock market on the 8th, the Dow Jones Average rose significantly by 683.04 points (+1.76%) to reach 39,446.49 dollars, and performed steadily throughout the day due to the weekly number of jobless claims being lower than expected, which eased concerns about the deterioration of the labor market and the economy. The upward momentum increased towards the end of the day. Buying is expected to be the dominant trend in today's emerging markets, as major indices in the US stock market rebounded significantly yesterday.
Stocks that were active the previous day Part 2, Metaplanet, Japan Electronic Materials, Japan Information C, etc.
Brand Name <Code> 8 Day Closing Price ⇒ Compared to Previous Day Skypa J <9412> 728 -1017 Accounting during the day is viewed negatively. Miyachi Engineering Group <3431> 3945 -325 Progress rate for the first quarter is viewed negatively. Sumitomo Metal Mining <5713> 3585 -357 Actual profit excluding one-time items is kept according to the previous plan. Nippon Chemicon <6997> 1118 -88 Dislike the significant decline in earnings in the first quarter. Sumitomo Heavy Industries <6302> 31
Stem Inc, MDNT and others [Emerging Markets Press Release]
Acquired and subordinated the stock of Swaying Wind, who operates the WOLVES animal hospital. Started manufacturing specific cell products ('S-DSC') for hair regeneration under contract with MDNT. Registered patents (China) for peptides related to the peripheral peptides of LedaSemchidot (HMGB1 fragment peptide) at Stemlim Regenerative Induction Medicine. Massive exercise of Fanpep's 11th subscription rights (with modification clause for exercise price) to issue 0.67 million 4,000 shares starting from the first day.
FunPep: Confirmatory letter.
FunPep: Interim Report - 12th Term (2024/01/01 - 2024/06/30)
No Data